Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma.
<h4>Background</h4> <p>Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict re...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2017
|
| _version_ | 1797062248449966080 |
|---|---|
| author | Lee, R Gremel, G Marshall, A Myers, K Fisher, N Dunn, J Dhomen, N Corrie, P Middleton, M Lorigan, P Marais, R |
| author_facet | Lee, R Gremel, G Marshall, A Myers, K Fisher, N Dunn, J Dhomen, N Corrie, P Middleton, M Lorigan, P Marais, R |
| author_sort | Lee, R |
| collection | OXFORD |
| description | <h4>Background</h4> <p>Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.</p> <h4>Patients and methods</h4> <p>We carried out droplet digital polymerase chain reaction to detect BRAF and NRAS mutations in plasma taken after surgery from 161 stage II/III high-risk melanoma patients enrolled in the AVAST-M adjuvant trial.</p> <h4>Results</h4> <p>Mutant BRAF or NRAS ctDNA was detected (≥1 copy of mutant ctDNA) in 15/132 (11%) BRAF mutant patient samples and 4/29 (14%) NRAS mutant patient samples. Patients with detectable ctDNA had a decreased disease-free interval [DFI; hazard ratio (HR) 3.12; 95% confidence interval (CI) 1.79–5.47; P<0.0001] and distant metastasis-free interval (DMFI; HR 3.22; 95% CI 1.80–5.79; P<0.0001) versus those with undetectable ctDNA. Detectable ctDNA remained a significant predictor after adjustment for performance status and disease stage (DFI: HR 3.26, 95% CI 1.83–5.83, P<0.0001; DMFI: HR 3.45, 95% CI 1.88–6.34, P<0.0001). Five-year overall survival rate for patients with detectable ctDNA was 33% (95% CI 14%–55%) versus 65% (95% CI 56%–72%) for those with undetectable ctDNA. Overall survival was significantly worse for patients with detectable ctDNA (HR 2.63; 95% CI 1.40–4.96); P=0.003) and remained significant after adjustment for performance status (HR 2.50, 95% CI 1.32–4.74, P=0.005).</p> <h4>Conclusion</h4> <p>ctDNA predicts for relapse and survival in high-risk resected melanoma and could aid selection of patients for adjuvant therapy.</p> |
| first_indexed | 2024-03-06T20:42:49Z |
| format | Journal article |
| id | oxford-uuid:34d1b208-cd65-495f-834d-192c16682889 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:42:49Z |
| publishDate | 2017 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:34d1b208-cd65-495f-834d-192c166828892022-03-26T13:28:33ZCirculating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:34d1b208-cd65-495f-834d-192c16682889EnglishSymplectic Elements at OxfordOxford University Press2017Lee, RGremel, GMarshall, AMyers, KFisher, NDunn, JDhomen, NCorrie, PMiddleton, MLorigan, PMarais, R <h4>Background</h4> <p>Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.</p> <h4>Patients and methods</h4> <p>We carried out droplet digital polymerase chain reaction to detect BRAF and NRAS mutations in plasma taken after surgery from 161 stage II/III high-risk melanoma patients enrolled in the AVAST-M adjuvant trial.</p> <h4>Results</h4> <p>Mutant BRAF or NRAS ctDNA was detected (≥1 copy of mutant ctDNA) in 15/132 (11%) BRAF mutant patient samples and 4/29 (14%) NRAS mutant patient samples. Patients with detectable ctDNA had a decreased disease-free interval [DFI; hazard ratio (HR) 3.12; 95% confidence interval (CI) 1.79–5.47; P<0.0001] and distant metastasis-free interval (DMFI; HR 3.22; 95% CI 1.80–5.79; P<0.0001) versus those with undetectable ctDNA. Detectable ctDNA remained a significant predictor after adjustment for performance status and disease stage (DFI: HR 3.26, 95% CI 1.83–5.83, P<0.0001; DMFI: HR 3.45, 95% CI 1.88–6.34, P<0.0001). Five-year overall survival rate for patients with detectable ctDNA was 33% (95% CI 14%–55%) versus 65% (95% CI 56%–72%) for those with undetectable ctDNA. Overall survival was significantly worse for patients with detectable ctDNA (HR 2.63; 95% CI 1.40–4.96); P=0.003) and remained significant after adjustment for performance status (HR 2.50, 95% CI 1.32–4.74, P=0.005).</p> <h4>Conclusion</h4> <p>ctDNA predicts for relapse and survival in high-risk resected melanoma and could aid selection of patients for adjuvant therapy.</p> |
| spellingShingle | Lee, R Gremel, G Marshall, A Myers, K Fisher, N Dunn, J Dhomen, N Corrie, P Middleton, M Lorigan, P Marais, R Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. |
| title | Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. |
| title_full | Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. |
| title_fullStr | Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. |
| title_full_unstemmed | Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. |
| title_short | Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. |
| title_sort | circulating tumor dna predicts survival in patients with resected high risk stage ii iii melanoma |
| work_keys_str_mv | AT leer circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT gremelg circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT marshalla circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT myersk circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT fishern circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT dunnj circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT dhomenn circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT corriep circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT middletonm circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT loriganp circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma AT maraisr circulatingtumordnapredictssurvivalinpatientswithresectedhighriskstageiiiiimelanoma |